A high-throughput drug screening identifies luteolin as a therapeutic candidate for pathological cardiac hypertrophy and heart failure
BackgroundPathological cardiac hypertrophy is commonly resulted from sustained pressure overload and/or metabolic disorder and eventually leads to heart failure, lacking specific drugs in clinic. Here, we aimed to identify promising anti-hypertrophic drug(s) for heart failure and related metabolic d...
Main Authors: | Zhenya Wang, Wei Shi, Taibo Wu, Tian Peng, Xiaoming Wang, Shuaiyang Liu, Zifeng Yang, Jia Wang, Peng-Long Li, Ruifeng Tian, Ying Hong, Hailong Yang, Lan Bai, Yufeng Hu, Xu Cheng, Hongliang Li, Xiao-Jing Zhang, Zhi-Gang She |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1130635/full |
Similar Items
-
Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
by: Zifeng Yang, et al.
Published: (2023-01-01) -
Honokiol acts as an AMPK complex agonist therapeutic in non-alcoholic fatty liver disease and metabolic syndrome
by: Ruifeng Tian, et al.
Published: (2023-03-01) -
The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD
by: Zifeng Yang, et al.
Published: (2023-05-01) -
Luteolin-β-CD-MOF prevents against acetaminophen-mediated liver damage by controlling ferroptosis through GSH/GPX4/SLC7A11 signal axis
by: Dan Yang, et al.
Published: (2024-05-01) -
Anti-Inflammatory and Active Biological Properties of the Plant-Derived Bioactive Compounds Luteolin and Luteolin 7-Glucoside
by: Sabrina Caporali, et al.
Published: (2022-03-01)